JP7419238B2 - Ｐｄ１結合剤 - Google Patents

Ｐｄ１結合剤 Download PDF

Info

Publication number
JP7419238B2
JP7419238B2 JP2020542297A JP2020542297A JP7419238B2 JP 7419238 B2 JP7419238 B2 JP 7419238B2 JP 2020542297 A JP2020542297 A JP 2020542297A JP 2020542297 A JP2020542297 A JP 2020542297A JP 7419238 B2 JP7419238 B2 JP 7419238B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515542A (ja
JP2021515542A5 (enExample
Inventor
ジェームズ ジョナサン フィンレー，ウィリアム
Original Assignee
ウルトラヒューマン エイト リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウルトラヒューマン エイト リミテッド filed Critical ウルトラヒューマン エイト リミテッド
Publication of JP2021515542A publication Critical patent/JP2021515542A/ja
Publication of JP2021515542A5 publication Critical patent/JP2021515542A5/ja
Application granted granted Critical
Publication of JP7419238B2 publication Critical patent/JP7419238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020542297A 2018-03-08 2019-03-08 Ｐｄ１結合剤 Active JP7419238B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB1803745.7A GB201803745D0 (en) 2018-03-08 2018-03-08 PD1 binding agents
GB1803745.7 2018-03-08
GB1807176.1 2018-05-01
GBGB1807176.1A GB201807176D0 (en) 2018-03-08 2018-05-01 PD1 Binding agents
GB1811302.7 2018-07-10
GBGB1811302.7A GB201811302D0 (en) 2018-03-08 2018-07-10 PD1 binding agents
GB1816372.5 2018-10-08
GBGB1816372.5A GB201816372D0 (en) 2018-03-08 2018-10-08 PD1 binding agents
GB1817652.9 2018-10-29
GBGB1817652.9A GB201817652D0 (en) 2018-03-08 2018-10-29 PD1 binding agents
PCT/EP2019/055901 WO2019170885A1 (en) 2018-03-08 2019-03-08 Pd1 binding agents

Publications (3)

Publication Number Publication Date
JP2021515542A JP2021515542A (ja) 2021-06-24
JP2021515542A5 JP2021515542A5 (enExample) 2022-03-15
JP7419238B2 true JP7419238B2 (ja) 2024-01-22

Family

ID=61972774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542297A Active JP7419238B2 (ja) 2018-03-08 2019-03-08 Ｐｄ１結合剤

Country Status (11)

Country Link
US (3) US10858434B2 (enExample)
EP (1) EP3762418A1 (enExample)
JP (1) JP7419238B2 (enExample)
KR (1) KR20200128544A (enExample)
CN (1) CN111819201A (enExample)
AU (1) AU2019229663A1 (enExample)
CA (1) CA3092169A1 (enExample)
GB (5) GB201803745D0 (enExample)
IL (1) IL277131A (enExample)
SG (1) SG11202008240RA (enExample)
WO (1) WO2019170885A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201914747D0 (en) * 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
CA3181776A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
CN116194471A (zh) 2020-06-23 2023-05-30 卡德门企业有限公司 抗pd-1抗体和融合蛋白
EP4353746A4 (en) * 2021-06-11 2024-12-04 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
US11981727B2 (en) * 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof
CN116253796A (zh) * 2022-09-21 2023-06-13 三优生物医药(上海)有限公司 靶向冠状病毒的中和抗体、其抗原结合片段及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016533763A (ja) 2013-09-13 2016-11-04 ベイジーン リミテッド 抗ｐｄ−１抗体並びにその治療及び診断のための使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218257A (zh) * 2005-03-25 2008-07-09 托勒克斯股份有限公司 Gitr结合分子及其用途
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
MA43028B1 (fr) * 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016533763A (ja) 2013-09-13 2016-11-04 ベイジーン リミテッド 抗ｐｄ−１抗体並びにその治療及び診断のための使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
mAbs，2013年，Vol. 5, No. 3，p. 445-470

Also Published As

Publication number Publication date
US10858434B2 (en) 2020-12-08
US20210047415A1 (en) 2021-02-18
GB201803745D0 (en) 2018-04-25
GB201807176D0 (en) 2018-06-13
GB201816372D0 (en) 2018-11-28
CA3092169A1 (en) 2019-09-12
EP3762418A1 (en) 2021-01-13
IL277131A (en) 2020-10-29
JP2021515542A (ja) 2021-06-24
AU2019229663A1 (en) 2020-10-15
SG11202008240RA (en) 2020-09-29
US11851460B2 (en) 2023-12-26
KR20200128544A (ko) 2020-11-13
US20200317785A1 (en) 2020-10-08
GB201817652D0 (en) 2018-12-12
WO2019170885A1 (en) 2019-09-12
US20240124590A1 (en) 2024-04-18
CN111819201A (zh) 2020-10-23
GB201811302D0 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
JP7458569B2 (ja) Ｃｄ４７結合剤
US10858435B2 (en) PD1 binding agents
US20240124590A1 (en) Pd1 binding agents
US12415861B2 (en) Anti C-MET antibodies
US10975165B2 (en) De-immunised anti-ERBB3 antibodies
US11655300B2 (en) Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240110

R150 Certificate of patent or registration of utility model

Ref document number: 7419238

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350